Literature DB >> 20557763

ICONE: An International Consortium of Neuro Endovascular Centres.

J Raymond1, P White, D F Kallmes, J Spears, T Marotta, D Roy, F Guilbert, A Weill, T Nguyen, A J Molyneux, H Cloft, S Cekirge, I Saatci, S Bracard, J F Meder, J Moret, C Cognard, A I Qureshi, A S Turk, A Berenstein.   

Abstract

SUMMARY: The proliferation of new endovascular devices and therapeutic strategies calls for a prudentand rational evaluation of their clinical benefit. This evaluation must be done in an effective manner and in collaboration with industry. Such research initiative requires organisation a land methodological support to survive and thrive in a competitive environment. We propose the formation of an international consortium, an academic alliance committed to the pursuit of effective neurovascular therapies. Such a consortium would be dedicated to the designand execution of basic science, device developmentand clinical trials. The Consortium is owned and operated by its members. Members are international leaders in neurointerventional research and clinical practice. The Consortium brings competency, knowledge, and expertise to industry as well as to its membership across aspectrum of research initiatives such as: expedited review of clinical trials, protocol development, surveys and systematic reviews; laboratory expertise and support for research design and grant applications to public agencies. Once objectives and protocols are approved, the Consortium provides a stable network of centers capable of timely realization of clinical trials or pre clinical investigations in an optimal environment. The Consortium is a non-profit organization. The potential revenue generated from clientsponsored financial agreements will be redirected to the academic and research objectives of the organization. The Consortium wishes to work inconcert with industry, to support emerging trends in neurovascular therapeutic development. The Consortium is a realistic endeavour optimally structured to promote excellence through scientific appraisal of our treatments, and to accelerate technical progress while maximizing patients' safety and welfare.

Entities:  

Year:  2008        PMID: 20557763      PMCID: PMC3313725          DOI: 10.1177/159101990801400213

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  14 in total

1.  Clinical trials in jeopardy.

Authors:  G C J M Cleophas; T J Cleophas
Journal:  Int J Clin Pharmacol Ther       Date:  2003-02       Impact factor: 1.366

2.  Tied up in red tape, European trials shut down.

Authors:  Brandon Keim
Journal:  Nat Med       Date:  2007-02       Impact factor: 53.440

Review 3.  Trial on endovascular treatment of unruptured aneurysms (TEAM): study monitoring and rationale for trial interruption or continuation.

Authors:  J Raymond; J F Meder; A J Molyneux; A J Fox; S C Johnston; J P Collet; I Rouleau
Journal:  J Neuroradiol       Date:  2007-03       Impact factor: 3.447

4.  Have you been smoking something that is biologically active?

Authors:  Harry J Cloft
Journal:  AJNR Am J Neuroradiol       Date:  2006-02       Impact factor: 3.825

Review 5.  Ready or not, here they come: randomized trials evaluating new endovascular aneurysm therapies.

Authors:  D F Kallmes; H J Cloft
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

6.  International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial.

Authors:  Andrew Molyneux; Richard Kerr; Irene Stratton; Peter Sandercock; Mike Clarke; Julia Shrimpton; Rury Holman
Journal:  Lancet       Date:  2002-10-26       Impact factor: 79.321

7.  New Devices Designed to Improve the Long-Term Results of Endovascular Treatment of Intracranial Aneurysms. A Proposition for a Randomized Clinical Trial to Assess their Safety and Efficacy.

Authors:  J Raymond; P Leblanc; M Chagnon; G Gévry; J P Collet; F Guilbert; A Weill; D Roy
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

8.  A randomized trial on the safety and efficacy of endovascular treatment of unruptured intracranial aneurysms is feasible.

Authors:  J Raymond; M Chagnon; J P Collet; F Guilbert; A Weill; D Roy
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

Review 9.  Interventional neuroradiology: the role of experimental models in scientific progress.

Authors:  J Raymond; I Salazkin; G Gevry; T N Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2007-03       Impact factor: 3.825

10.  Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators.

Authors:  H J Barnett; D W Taylor; M Eliasziw; A J Fox; G G Ferguson; R B Haynes; R N Rankin; G P Clagett; V C Hachinski; D L Sackett; K E Thorpe; H E Meldrum; J D Spence
Journal:  N Engl J Med       Date:  1998-11-12       Impact factor: 91.245

View more
  2 in total

1.  How everybody wins when playing by the rules: the benefits of investigator-initiated industry-sponsored clinical trials.

Authors:  W Brinjikji; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-03       Impact factor: 3.825

2.  Endovascular treatment of aneurysms and platinum coil caliber: Study protocol of a randomized, controlled trial.

Authors:  Jimmy Ghostine; Naim Khoury; Francis Cloutier; Marc Kotowski; Jean-Christophe Gentric; André L Batista; Alain Weill; Daniel Roy; Tim E Darsaut; Jean Raymond
Journal:  Interv Neuroradiol       Date:  2016-08-16       Impact factor: 1.610

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.